Skip to content
Science — Master Your Fitness Journey — Understanding & Managing Conditions — Master Your Money — Investing — Master Your Business — Technology

Irish Biotech Aerska Secures $21M for RNA Therapies

Aerska's innovative platform targets harmful genes in the brain. With $21M in funding, it's set to revolutionize treatment for neurological diseases and boost Ireland's biotech scene.

,   and  Administrator
1 min read
This seems like a printer box and there is a paper is on that, there is a text "Stop talking" is...
This seems like a printer box and there is a paper is on that, there is a text "Stop talking" is written on the paper and there is an another paper placed on the table and there is a text " Fucking genius" is written.

Irish Biotech Aerska Secures $21M for RNA Therapies

Irish biotech start-up Aerska has secured $21 million (€18 million) in seed funding. The company, founded by Jack O'Meara, Dave Hardwicke, and Stu Milstein, is developing RNA-based therapies for degenerative neurological diseases such as Alzheimer's and Parkinson's. Led by Backed VC and Age1, Aerska aims to revolutionize treatment options for these debilitating conditions.

Aerska's innovative antibody-oligo conjugate (AOC) platform uses 'brain shuttles' for systemic RNAi delivery. This technology allows the company to target and switch off harmful genes, potentially treating, delaying, and preventing degenerative neurological diseases. The funding round, which also included investments from Blueyard, Lingotto, Kerna Ventures, Norrsken, and Speedinves, will be used to expand operations in Dublin and London, and accelerate drug discovery.

The company is actively engaging with Ireland's university and research ecosystem, exploring potential collaborations. Minister for Enterprise, Tourism and Employment, Peter Burke, has expressed support for Aerska's growth, highlighting Ireland's ambition to become a global leader in biotechnology. Aerska plans to build a team of seasoned drug developers in Dublin and a research team in London, creating jobs and ensuring Ireland remains at the forefront of developing life-changing technologies and medicines.

Aerska's successful seed funding round positions the company to advance its RNA-based therapies for degenerative neurological diseases. With support from the Irish government and the country's robust research ecosystem, Aerska is poised to create jobs and contribute to Ireland's growing reputation as a biotechnology hub.

Read also:

Related

Latest